Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2
Technology appraisal guidance
Reference number: TA257
Published:
Tools and resources
Tools and resources to help you put the guidance into practice.